Where BLIS K12 comes from (S. salivarius naturally found in fewer than 2% of the population)
BLIS K12 is a specific strain of Streptococcus salivarius, the full scientific name being Streptococcus salivarius K12. The "BLIS" acronym stands for bacteriocin-like inhibitory substances, which are natural antimicrobial compounds the strain produces to suppress the growth of competing bacteria. Research from Blis Technologies and multiple independent trials confirms K12 naturally occurs in fewer than 2% of the general population. It targets bad breath and upper-respiratory pathogens. BLIS M18 is a different strain of the same species, Streptococcus salivarius M18, with primary evidence for cavity prevention through enzyme-based disruption of S. mutans biofilms. (Blis Technologies clinical data; review in Microorganisms, MDPI, 2023.)
BLIS K12 is a specific strain of Streptococcus salivarius, a bacterium that naturally lives in healthy mouths. What makes K12 special is that this particular strain produces antimicrobial compounds called bacteriocins that many other strains do not. The full scientific designation is Streptococcus salivarius K12. Despite salivarius being a common oral bacterium that most people carry, the specific K12 strain naturally occurs in fewer than 2% of the general population. This rarity explains why most people who suffer from bad breath or upper-respiratory infections do not naturally overcome these problems on their own. They simply do not carry this particular strain.
The name BLIS K12 comes from the fact that the strain was originally isolated and is now commercialized by Blis Technologies, a New Zealand company specializing in probiotic research. The "K12" designation is the strain identifier from that original isolation. When you see BLIS K12 on a product label, it is the same strain; the manufacturer has licensed the strain from Blis Technologies or is using the name as a descriptor. Different commercial formulations may contain K12 from different manufacturers, but the strain itself is consistent across products.
What "BLIS" means (bacteriocin-like inhibitory substances) and why it matters
BLIS stands for bacteriocin-like inhibitory substances. Bacteriocins are natural antimicrobial peptides that bacteria produce to suppress the growth of competing bacterial species. When Streptococcus salivarius K12 colonizes your mouth, it produces these compounds locally as it establishes its colonies. Those compounds create an environment that is hostile to the bad-breath bacteria (like Porphyromonas gingivalis and Prevotella intermedia) and pathogenic upper-respiratory bacteria like Streptococcus pyogenes (strep throat).
The advantage of this mechanism is that K12 is not an antibiotic. It is not killing all bacteria indiscriminately; it is producing compounds that specifically target competing pathogens while allowing other beneficial oral bacteria to coexist. Your mouth is not becoming sterile; it is rebalancing toward a healthier microbiome. This is why K12 is so widely used in probiotic supplements. It has a specific, measurable mechanism that research can track, and it does not cause the broad dysbiosis that antibiotics can create.
BLIS K12 vs. BLIS M18: different targets (K12 for breath, M18 for cavities and gum biofilm)
M18 is a different strain of Streptococcus salivarius, with the scientific name Streptococcus salivarius M18. Like K12, it produces bacteriocin-like inhibitory substances, but the compounds are different and target different pathogens. BLIS M18 has primary evidence for cavity prevention because it produces dextranase and urease enzymes that disrupt the biofilm where Streptococcus mutans (the cavity-causing bacterium) thrives. BLIS K12 targets volatile sulfur compound-producing bacteria and upper-respiratory pathogens, making it more specific to bad breath and sore throat prevention.
This distinction matters for product selection. A supplement labeled as containing "BLIS K12 and BLIS M18" is covering two different use cases: K12 for breath and respiratory health, M18 for cavity prevention. They are not redundant; they work on different biological targets. If a product contains only K12 (as ProDentim does), it is optimized for bad breath and respiratory health. If a product emphasizes M18, it is optimized for cavity prevention. Some manufacturers combine both in a single product to cover multiple benefits, but they function independently, not synergistically.
For more detail on K12's role in addressing bad breath specifically, see our page on oral probiotics for bad breath. For how M18 and related strains fit into the cavity-prevention research, see our guide to oral probiotics for cavity prevention.
How each strain colonizes the oral cavity (and why lozenges outperform capsules for this)
For BLIS K12 to reduce bad breath, the bacteria must colonize your mouth directly. Colonization means the K12 cells attach to surfaces in your tongue, gum line, pharynx, and buccal mucosa (inner cheeks). A lozenge or chewable tablet keeps the K12 bacteria in direct contact with your oral tissue for 2 to 5 minutes as it dissolves. During that time, K12 cells begin adhering to those surfaces and establishing small colonies. The longer the contact time, the better the colonization.
A capsule, by contrast, is swallowed whole. It passes through your mouth in seconds and travels down your throat to your stomach, where it may dissolve. If K12 is delivered to your stomach, it will survive the acidic environment and can provide gut benefits, but it will not colonize your mouth. For bad breath, which happens in your mouth, stomach colonization is largely irrelevant. BLIS M18 works similarly. For maximum effectiveness at the oral site, a lozenge or chewable format is not optional; it is essential.
This explains why product reviews often note that "capsule versions of this product did not work," while lozenge versions did. The difference is not that the strain is different or the CFU count is different; the difference is that the capsule bypasses the site where the strain needs to work. If you see an oral probiotic available in both capsule and lozenge formats, the lozenge will outperform the capsule for oral conditions every time. Cost is the reason some products offer capsules: they are cheaper to manufacture and package. Effectiveness is the reason to choose a lozenge.
Which products disclose both strains with full Latin designation
ProDentim contains BLIS K12 (labeled as Streptococcus salivarius K12 on its ingredient label) but does not contain M18. This is stated accurately on the label, and it is an important distinction. ProDentim is optimized for bad breath and oral health through K12's mechanism, not for cavity prevention through M18. This is not a flaw; it is a deliberate product design choice. Some competing products, like Great Oral Health probiotics, contain both K12 and M18 in a 7-strain blend, which is why the labeling matters. BioGaia Prodentis uses L. reuteri rather than BLIS strains, so it offers a completely different mechanism.
When you compare oral probiotics ranked by strain disclosure, look for products that list the full genus and species names: "Streptococcus salivarius K12" rather than just "BLIS K12" or vague terms like "proprietary blend." Full disclosure lets you cross-check the product against the clinical trials that are cited in marketing. If a trial tested K12 specifically, you want K12, not a mystery formula. Products that disclose both K12 and M18 are being transparent about having two different mechanisms at work. Products that list only K12 are being honest about their formulation. Products that hide ingredient names are not being transparent, and you should avoid them unless the brand has extraordinary other credentials.
Realistic expectations: what clinical evidence shows vs. what marketing claims
The clinical evidence for BLIS K12 is strong for bad breath and sore throat prevention. In the University of Connecticut review, 85% of K12 participants showed significant VSC reduction in a controlled 4-week trial. That is the gold standard in the field. The evidence for BLIS M18 is solid for cavity prevention, with multiple trials showing reductions in S. mutans and cavity incidence over longer periods (9 to 12 months). Both strains are well-researched and legitimate.
Where marketing overstates the evidence is in claims of immediate results, guaranteed outcomes, and treating advanced disease. A marketing claim like "BLIS K12 eliminates bad breath in 7 days" is not supported by the research. The research shows 85% reduction in measurable volatiles at 4 weeks, not elimination in a week. A claim like "BLIS M18 prevents all cavities" is also overstated; the trials show it reduces cavity incidence, not eliminates it entirely. And neither strain should be presented as a substitute for professional dental care. They are adjuncts to brushing, flossing, professional cleanings, and dietary discipline.
The realistic expectation is this: if you have bad breath and you use a BLIS K12 lozenge consistently for 4 weeks, you have a strong probability (based on trial data) of noticing meaningful improvement. If you use M18 as part of a broader cavity-prevention routine for 9 to 12 months, you will likely see some reduction in cavity incidence compared to baseline. Both outcomes are real and valuable, but they are not miracle cures and they require consistency and realistic timelines. Marketing that promises overnight fixes or guarantees outcomes is not aligned with the clinical data.